161 related articles for article (PubMed ID: 38563112)
21. [Comparison of high-risk human papillomavirus infection rate and genotype distribution between Han and Mongolian women].
Zhao S; Zhao XL; Hu SY; Wang Y; Remila R; Xu XQ; Duan XZ; Chen F; Zhang X; Zhao FH
Zhonghua Liu Xing Bing Xue Za Zhi; 2019 Nov; 40(11):1439-1444. PubMed ID: 31838818
[No Abstract] [Full Text] [Related]
22. Effectiveness of High-risk Human Papillomavirus Testing for Cervical Cancer Screening in China: A Multicenter, Open-label, Randomized Clinical Trial.
Zhang J; Zhao Y; Dai Y; Dang L; Ma L; Yang C; Li Y; Kong L; Wei L; Zhang S; Liu J; Xi M; Chen L; Duan X; Xiao Q; Abulizi G; Zhang G; Hong Y; Gao X; Zhou Q; Xie X; Li L; Niyazi M; Zhang Z; Tuo J; Ding Y; Si M; Chen F; Song L; Qiao Y; Lang J
JAMA Oncol; 2021 Feb; 7(2):263-270. PubMed ID: 33377903
[TBL] [Abstract][Full Text] [Related]
23. Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting.
Leinonen M; Nieminen P; Kotaniemi-Talonen L; Malila N; Tarkkanen J; Laurila P; Anttila A
J Natl Cancer Inst; 2009 Dec; 101(23):1612-23. PubMed ID: 19903804
[TBL] [Abstract][Full Text] [Related]
24. Prevalence of higher-grade dysplasia in persistently high-risk human papillomavirus positive, cytology negative women after introduction of the new cervical cancer screening in Germany.
Berger L; Wolf-Breitinger M; Weiß C; Tuschy B; Berlit S; Sütterlin M; Spaich S
Cancer Causes Control; 2023 May; 34(5):469-477. PubMed ID: 36854989
[TBL] [Abstract][Full Text] [Related]
25. Clinical determinants of a positive visual inspection after treatment with acetic acid for cervical cancer screening.
Castle PE; Qiao YL; Zhao FH; Chen W; Valdez M; Zhang X; Kang LN; Bansil P; Paul P; Bai P; Peck R; Li J; Chen F; Jeronimo J
BJOG; 2014 May; 121(6):739-46. PubMed ID: 24575872
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral.
Kulasingam SL; Hughes JP; Kiviat NB; Mao C; Weiss NS; Kuypers JM; Koutsky LA
JAMA; 2002 Oct; 288(14):1749-57. PubMed ID: 12365959
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of several screening approaches for detection of cervical lesions in rural Shandong, China.
Zong LJ; Zhang YZ; Yang XS; Jiang J; Cui BX; Qiao YB; Li L; Jiang K; Zhang WJ; Kong BH; Shen K
Asian Pac J Cancer Prev; 2015; 16(5):1907-12. PubMed ID: 25773843
[TBL] [Abstract][Full Text] [Related]
28. Implementation of HPV-based Cervical Cancer Screening Combined with Self-sampling Using a Midwifery Network Across Rural Greece: The GRECOSELF Study.
Agorastos T; Chatzistamatiou K; Tsertanidou A; Mouchtaropoulou E; Pasentsis K; Kitsou A; Moysiadis T; Moschaki V; Skenderi A; Katsiki E; Aggelidou S; Venizelos I; Ntoula M; Daponte A; Vanakara P; Garas A; Stefos T; Vrekoussis T; Lymberis V; Kontomanolis EN; Makrigiannakis A; Manidakis G; Deligeoroglou E; Panoskaltsis T; Decavalas GO; Michail G; Kalogiannidis I; Koukoulis G; Zempili P; Halatsi D; Truva T; Piha V; Agelena G; Chronopoulou A; Vaitsi V; Chatzaki E; Paschopoulos M; Adonakis G; Kaufmann AM; Hadzidimitriou A; Stamatopoulos K
Cancer Prev Res (Phila); 2019 Oct; 12(10):701-710. PubMed ID: 31427275
[TBL] [Abstract][Full Text] [Related]
29. Lower cost strategies for triage of human papillomavirus DNA-positive women.
Qiao YL; Jeronimo J; Zhao FH; Schweizer J; Chen W; Valdez M; Lu P; Zhang X; Kang LN; Bansil P; Paul P; Mahoney C; Berard-Bergery M; Bai P; Peck R; Li J; Chen F; Stoler MH; Castle PE
Int J Cancer; 2014 Jun; 134(12):2891-901. PubMed ID: 24248915
[TBL] [Abstract][Full Text] [Related]
30. Cross-sectional study of HPV testing in self-sampled urine and comparison with matched vaginal and cervical samples in women attending colposcopy for the management of abnormal cervical screening.
Sargent A; Fletcher S; Bray K; Kitchener HC; Crosbie EJ
BMJ Open; 2019 Apr; 9(4):e025388. PubMed ID: 31036707
[TBL] [Abstract][Full Text] [Related]
31. Management of HPV-positive women in cervical screening using results from two consecutive screening rounds.
Polman NJ; Veldhuijzen NJ; Heideman DAM; Snijders PJF; Meijer CJLM; Berkhof J
Int J Cancer; 2019 May; 144(9):2339-2346. PubMed ID: 30565673
[TBL] [Abstract][Full Text] [Related]
32. [Effectiveness of Different Testing Strategies Applied for Cervical Cancer Screening in Shuangliu District, Chengdu City].
Zeng X; Li J; Kang LN; Yan LP; He Z; Liao GD; Xi MR; Chen MY
Sichuan Da Xue Xue Bao Yi Xue Ban; 2022 Sep; 53(5):896-903. PubMed ID: 36224694
[TBL] [Abstract][Full Text] [Related]
33. Concurrent Cervical and Anal High-Risk Human Papillomavirus Infection in Women Living With HIV: An Observational Case-Control Study.
Gupta R; Hussain S; Hariprasad R; Dhanasekaran K; Verma S; Agarwal V; Das PK; Singh S; Gupta S
J Acquir Immune Defic Syndr; 2022 Nov; 91(3):319-324. PubMed ID: 35916635
[TBL] [Abstract][Full Text] [Related]
34. Determining the prevalence of high-risk human papillomavirus infection using a novel cervical precancer screening approach in incarcerated women at the Nsawam Medium Security Prison, Ghana.
Acheampong LK; Effah K; Amuah JE; Tekpor E; Wormenor CM; Gedzah I; Kemawor S; Kachana AC; Danso PA; Essel NOM; Asomaning M; Agyiri D; Akakpo PK
Ecancermedicalscience; 2021; 15():1248. PubMed ID: 34267804
[TBL] [Abstract][Full Text] [Related]
35. Human papillomavirus-based cervical precancer screening with visual inspection with acetic acid triage to achieve same-day treatments among women living with human immunodeficiency virus infection: test-of-concept study in Ibadan, Nigeria.
Awolude OA; Oyerinde SO; Ayeni AO; Adewole IF
Pan Afr Med J; 2021; 40():48. PubMed ID: 34795828
[TBL] [Abstract][Full Text] [Related]
36. Experience of Combined Liquid Based Cervical Cytology and High-Risk HPV mRNA for Cervical Cancer Screening in Thammasat University Hospital.
Muangto T; Chanthasenanont A; Lertvutivivat S; Nanthakomon T; Pongrojpaw D; Bhamarapravatana K; Suwannarurk K
Asian Pac J Cancer Prev; 2016; 17(9):4409-4413. PubMed ID: 27797253
[TBL] [Abstract][Full Text] [Related]
37. Cytology compared with Hybrid Capture 2 human papilloma virus cervical cancer screening in HIV positive and HIV negative South African women.
Snyman LC; Richter KL; Lukhwareni A; Dreyer G; Botha MH; Van Der Merwe FH; Visser C; Dreyer G
Int J Gynecol Cancer; 2023 May; 33(5):669-675. PubMed ID: 36650011
[TBL] [Abstract][Full Text] [Related]
38. [Prevalence of high-risk HPV and its distribution in cervical precancerous lesions among 35-64 years old women who received cervical cancer screening in Beijing].
Shen J; Gao LL; Zhang Y; Han LL; Wang JD
Zhonghua Yu Fang Yi Xue Za Zhi; 2018 May; 52(5):493-497. PubMed ID: 29747341
[No Abstract] [Full Text] [Related]
39. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study.
Castle PE; Stoler MH; Wright TC; Sharma A; Wright TL; Behrens CM
Lancet Oncol; 2011 Sep; 12(9):880-90. PubMed ID: 21865084
[TBL] [Abstract][Full Text] [Related]
40. Determination of the diagnostic accuracy of testing for high-risk (HR) human papillomavirus (HPV) types 16, 18 and 45 in precancerous cervical lesions: preliminary data.
Tiews S; Steinberg W; Schneider W; Hanrath C
J Clin Virol; 2009 Nov; 46 Suppl 3():S11-5. PubMed ID: 20129068
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
